Loqtorzi Injection
Product Images NDC 70114-340

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Loqtorzi (NDC 70114-340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Coherus Oncology, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Loqtorzi 01)

Kaplan-Meier survival curve graph showing overall survival percentage over months for two groups: Toripalimab plus chemotherapy versus Placebo plus chemotherapy. The vertical axis represents overall survival percentage, and the horizontal axis represents time in months up to 54. The number of patients at risk is listed below the graph for each group at various time points. The solid black line represents Toripalimab plus chemotherapy, the dashed gray line represents Placebo plus chemotherapy, and vertical ticks indicate censored data points.*

FDA Label Image

Principal Display Panel (240 mg/6 mL Vial Carton)

LOQTORZI (toripalimab-tpzi) injection label showing 240 mg per 6 mL (40 mg/mL) strength. The label indicates it is for intravenous infusion after dilution and is a single-dose vial with instructions to discard unused portions. The NDC number 70114-340-01 and Rx Only designation are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.